Stonehage Fleming Financial Services Holdings LTD Gilead Sciences, Inc. Transaction History

Stonehage Fleming Financial Services Holdings LTD

$3.78 Billion
Q3 2024

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$71.58 - $87.29 $1.12 Million - $1.36 Million	15,599 New	15,599 $1.14 Million
Q3 2023 Nov 01, 2023	SELL	$73.94 - $80.67 $294,281 - $321,066	-3,980 Reduced 59.68%	2,689 $201,000
Q2 2023 Aug 10, 2023	SELL	$76.01 - $86.7 $678,769 - $774,231	-8,930 Reduced 57.25%	6,669 $513,000
Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $99,712 - $143,152	-1,600 Reduced 9.3%	15,599 $1.34 Million
Q2 2022 Aug 05, 2022	SELL	$57.72 - $65.01 $86,580 - $97,515	-1,500 Reduced 8.02%	17,199 $1.06 Million
Q4 2021 Feb 02, 2022	SELL	$64.88 - $73.64 $90,767 - $103,022	-1,399 Reduced 6.96%	18,699 $1.36 Million
Q3 2021 Nov 09, 2021	SELL	$67.69 - $73.03 $7,445 - $8,033	-110 Reduced 0.54%	20,098 $1.41 Million
Q2 2021 Aug 06, 2021	SELL	$63.47 - $69.35 $60,931 - $66,576	-960 Reduced 4.54%	20,208 $1.39 Million
Q1 2021 May 10, 2021	SELL	$60.0 - $68.46 $461,400 - $526,457	-7,690 Reduced 26.65%	21,168 $1.37 Million
Q4 2020 Feb 17, 2021	SELL	$56.65 - $64.55 $594,825 - $677,775	-10,500 Reduced 26.68%	28,858 $1.68 Million
Q3 2020 Nov 12, 2020	SELL	$62.1 - $78.08 $43,780 - $55,046	-705 Reduced 1.76%	39,358 $2.48 Million
Q2 2020 Aug 13, 2020	BUY	$72.34 - $84.0 $441,491 - $512,652	6,103 Added 17.97%	40,063 $3.08 Million
Q1 2020 May 13, 2020	BUY	$62.63 - $80.22 $770,349 - $986,706	12,300 Added 56.79%	33,960 $2.54 Million
Q4 2019 Feb 12, 2020	SELL	$61.62 - $67.78 $285,916 - $314,499	-4,640 Reduced 17.64%	21,660 $1.41 Million
Q3 2019 Oct 29, 2019	BUY	$62.51 - $69.0 $33,755 - $37,260	540 Added 2.1%	26,300 $1.67 Million
Q1 2019 Oct 11, 2019	SELL	$62.53 - $70.05 $260,750 - $292,108	-4,170 Reduced 13.93%	25,760 $1.68 Million
Q3 2018 Oct 11, 2019	BUY	$71.28 - $78.92 $92,664 - $102,596	1,300 Added 4.54%	29,930 $2.29 Million
Q2 2018 Oct 11, 2019	SELL	$64.88 - $75.68 $249,787 - $291,368	-3,850 Reduced 11.85%	28,630 $2.03 Million
Q1 2018 Oct 11, 2019	SELL	$72.84 - $88.8 $521,243 - $635,452	-7,156 Reduced 18.05%	32,480 $2.45 Million
Q4 2017 Oct 11, 2019	SELL	$71.15 - $83.52 $1.14 Million - $1.34 Million	-16,090 Reduced 28.87%	39,636 $2.84 Million
Q3 2017 Oct 11, 2019	BUY	$72.11 - $85.47 $752,107 - $891,452	10,430 Added 23.03%	55,726 $4.52 Million
Q2 2017 Oct 11, 2019	SELL	N/A	-22,535 Reduced 33.22%	45,296 $3.21 Million
Q1 2017 Oct 11, 2019	SELL	N/A	-44,321 Reduced 39.52%	67,831 $4.61 Million
Q4 2016 Oct 11, 2019	SELL	N/A	-4,170 Reduced 3.58%	112,152 $8.06 Million
Q3 2016 Oct 11, 2019	BUY	N/A	11,324 Added 10.78%	116,322 $9.2 Million
Q2 2016 Oct 11, 2019	BUY	N/A	9,700 Added 10.18%	104,998 $8.76 Million
Q1 2016 Oct 11, 2019	BUY	N/A	36,546 Added 62.2%	95,298 $8.75 Million
Q4 2015 Oct 11, 2019	SELL	N/A	-622 Reduced 1.05%	58,752 $5.95 Million
Q3 2015 Oct 11, 2019	BUY	N/A	4,520 Added 8.24%	59,374 $5.83 Million
Q2 2015 Oct 11, 2019	BUY	N/A	11,600 Added 26.82%	54,854 $6.42 Million
Q4 2014 Oct 11, 2019	BUY	N/A	43,254	43,254 $4.08 Million

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

Black Rock Inc. New York, NY

121M
Shares

$11.2 Billion
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$10.7 Billion
0.18% of portfolio
Capital World Investors Los Angeles, CA

76.5M
Shares

$7.09 Billion
1.03% of portfolio
Capital Research Global Investors Los Angeles, CA

61.8M
Shares

$5.72 Billion
1.12% of portfolio
State Street Corp Boston, MA

60.2M
Shares

$5.57 Billion
0.21% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Stonehage Fleming Financial Services Holdings LTD, based on Form 13F filings with the SEC.

News

Stay updated on Stonehage Fleming Financial Services Holdings LTD with notifications on news.

Account